Drug prices are even lower if the basic drug uniform pricing speed

Business News Agency June 2 According to media reports, the National Development and Reform Commission is sizing the basic pricing of basic drugs and has selected 50 varieties as pilots. We hope to encourage manufacturers to seek better drug quality control on the “red line” of prices.

In addition, the six domestic pharmaceutical industry associations called for the reform of "only low price is to take" the reform of drug bidding, and suggested that for retail varieties with a guide price below 10 yuan, only companies should be recruited not to raise prices.

Reunification pilot pricing

“The National Development and Reform Commission is exploring the implementation of uniform national pricing for essential medicines, and will eventually implement the practice of recruiting only manufacturers, recruiting services, and not urging prices.” This is the message revealed by Song Dayai at the National Pharmaceutical Trade Fair held in Nanchang in December last year.

This news has now been drafted and has been passed on for more than a month. According to the draft of the "fangfang" version received by the reporter, the National Development and Reform Commission will gradually implement the unified national pricing for the drugs in the "National Essential Drug List" in accordance with the principles of gradual and orderly and batch-phased distribution. The types of products that are uniformly priced by the state are, in principle, the exclusive varieties of basic medicines and the varieties that have been basically stable and have sufficient supply prices after many times of centralized bidding. In addition to clinical shortages and first-aid medicines, a number of manufactured varieties should be awarded more than three consecutive times in more than two-thirds of the country's provinces and cities.

The draft of the consultation also stated: “This move is an important measure to further improve the basic drug system, which is conducive to regulating the behavior of market purchases and sales, maintaining the normal market competition order, giving full play to the incentives and constraints of price levers on producers and operators, and ensuring that the basic drugs are normal. Production, supply and quality are safe and effective.”

The reporter interviewed a number of pharmaceutical companies and discovered that the basic drugs or the pricing of the trials was already an open secret in the industry. Tao Desheng, deputy president of Livzon Group, told reporters that the National Development and Reform Commission means that some varieties may be piloted first. "In fact, all kinds of pilot programs are currently available, but the problem of price is not that simple, and the overall promotion will not be so fast. At present, the industry's appeal is mainly due to the fact that the technical threshold for 'double envelope' is too low. view."

The "double envelope" system needs to be modified

The problem that Tao Desheng mentioned that the technical threshold is too low has recently been highlighted.

The “double envelope” system for creating basic medicines for bidding in Anhui has been used as a template and is required to be promoted nationwide. Due to the low technical threshold for the inspection of enterprises and product indicators, basically 70% of the companies can successfully pass, and the economic and technical targets do not bring the next commercial bid, this mechanism virtually obliges the industry's Spelling "business standards" and eventually leading to basic drug bidding fell into a price war of "only low price is taken".

China Pharmaceutical Industry Research and Development Promotion Association, China Pharmaceutical Enterprise Management Association, China Chemical Pharmaceutical Industry Association, China Association of Chinese Medicine, China Pharmaceutical Quality Management Association, China Non-prescription Drug Association and other six pharmaceutical industry associations together held a symposium to reflect on The pharmaceutical industry has embarked on the institutional flaw of "demonstration" and discussed the feasibility of issuing relevant reform proposals.

On May 31st, an article titled “Six Medicines Association Co-authored the State Council Medical Reform Office and related ministries and commissions, proposed to amend and perfect the “double envelope” system for tendering basic medicines” was put on the official website of the China Pharmaceutical Industry Research and Development Association.

Song Ruilin, executive president of the association, subsequently confirmed to the reporter that the above-mentioned six major medical associations have jointly signed the State Council Medical Reform Office and related ministries and commissions, and proposed to amend and perfect the "double envelope" system for bidding for essential medicines.

Song Ruilin said that the "proposal" that was formally written was the final version that was widely discussed and revised in the industry. The purpose was to coordinate national policies and advance the basic drug system.

The "Proposal" obtained by the reporter shows that the threshold for drug quality in the economic and technological tenders in the "double envelope" system is too low and is in a formality, and the rules and practices for the bid evaluation of the commercial tenders from the lowest bidder and the "quality priority, price The "reasonable" policy requirements are inconsistent. The appeals of the proposals mainly focus on the following four points:

First of all, the "Proposal" believes that the economic and technological tenders should effectively play a role in the threshold of basic drug quality, change the practice of pursuing only "quality assurance", and truly reflect the "quality first" principle. It is recommended that the State establish a unified and quantifiable comprehensive evaluation index system for basic pharmaceutical manufacturers to ensure that only pharmaceutical companies with integrity, quality, strength, and social responsibility can enter the procurement scope of basic drug bidding.

Secondly, the "Proposal" believes that the scores of the economic and technical standards of participating bidders should be brought into the evaluation of the commerce standard, and that they should be given greater weight. Finally, the target enterprises should be selected through comprehensive evaluation; all companies that manufacture and sell counterfeit medicines should be prohibited. Enter the basic drug market.